NeoGenomics, Inc. (NEO) Earnings Call Analysis

NASDAQ · Healthcare · Diagnostics & Research

23/25

Growth 5 Margin 5 Expansion 5 Platform 3 Financial 5

latest quarter score

Earnings Reports

23
NeoGenomics (NEO) Q2 2026: NGS Revenue Jumps 26% as High-Value Testing Drives Margin Expansion
July 29, 2026
18
NeoGenomics (NEO) Q1 2026: NGS Jumps 26% as Portfolio Shift Drives Margin and Market Share
April 29, 2026
19
NeoGenomics (NEO) Q4 2025: NGS Revenue Jumps 23% as High-Value Test Shift Reshapes Growth Trajectory
February 24, 2026
17
NeoGenomics (NEO) Q3 2025: NGS Revenue Jumps 24% as Community Oncology Penetration Deepens
October 28, 2025
14
NeoGenomics (NEO) Q2 2025: Pharma Revenue Down 26%, Shifting Focus to Clinical Expansion and NGS Mix
July 29, 2025
18
NeoGenomics (NEO) Q1 2025: NGS Drives 22% of Clinical Revenue as Community Oncology Focus Deepens
July 07, 2025

Browse all companies